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ADAM10 Is the Constitutive Functional Sheddase of
CD44 in Human Melanoma Cells
Ulf Anderegg1, Thea Eichenberg1, Tanja Parthaune1, Christian Haiduk1, Anja Saalbach1, Linda Milkova1,
Andreas Ludwig2, Jens Grosche3, Marco Averbeck1, Carl Gebhardt1, Verena Voelcker1, Jonathan P. Sleeman4
and Jan C. Simon1
CD44 proteins are cell surface receptors for hyaluronic acid (HA), a component of the extracellular matrix that
has multiple effects on cell behavior. CD44 can be shed from the cell surface by proteolytic cleavage. The
resulting soluble form can interfere with the interaction between HA and membrane-bound CD44. Soluble
CD44 can abolish the cell proliferation-promoting effect of HA on melanoma cell lines, suggesting that a better
understanding of the shedding process might identify ways of blocking tumor cell proliferation. ADAM10,
ADAM17, and MMP14 have previously been implicated in the shedding of CD44 from various tumor cells. Using
immunohistochemistry we demonstrate that ADAM10 and ADAM17 but not MMP14 are significantly expressed
on melanoma cells in histological sections. In human melanoma cell lines expression of these proteases could
be blocked by transfection with appropriate siRNAs. However, only blocking of ADAM10 expression led to
decreased shedding of CD44. In parallel, cell proliferation was promoted. Confocal microscopy demonstrated
that ADAM10 and CD44 colocalize on the cell surface. We conclude that ADAM10 is the predominant protease
involved in the constitutive shedding of endogenous CD44 from melanoma cells, and that enhancement of
ADAM10 activity could be an approach to decrease the proliferation of melanoma cells.
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INTRODUCTION
CD44 constitutes a family of transmembrane glycoproteins
that are generated by alternative splicing and glycosylation,
resulting in a variety of related proteins that range in size from
85 to 200 kDa and that regulate a number of aspects of cell
behavior (Naor et al., 1997). This regulatory activity is
mediated in part through the ability of CD44 proteins to
interact with hyaluronic acid (HA; Aruffo et al., 1990), a major
component of the extracellular matrix. The interaction
between HA and CD44 has multiple effects on cell prolifera-
tion, cell motility, and cell survival for both malignant and
nonmalignant cells (Goebeler et al., 1996; Naor et al., 1997;
Morrison et al., 2001; Ahrens et al., 2001a, b).
CD44s, the standard CD44 isoform that lacks epitopes
encoded by the variant exons, is 85–90 kDa in size and binds
strongly to HA (Stamenkovic et al., 1991). It is widely
expressed in different tissues and cell types, and furthermore
its expression is enhanced in a variety of malignant tumors
(Dietrich et al., 1997; Naor et al., 1997). Previously we have
shown that CD44s is the principal HA receptor expressed on
the surface of human melanoma cells (MM; Ahrens et al.,
2001a, b). Moreover, we could demonstrate that HA pro-
motes the proliferation of MM cells and that this is fully
dependent on the interaction between CD44 and HA (Ahrens
et al., 2001a).
In addition to binding to HA, CD44 can also serve as an
organizing platform for other proteins. For example, it directs
proteases such as MMP9 (Yu and Stamenkovic, 1999), MMP7
(Yu et al., 2002), and MMP14 (Mori et al., 2002) to the
leading edge of migrating cells. CD44 also functionally
interacts with growth factors (Bennett et al., 1995) and growth
factor receptors such as EGFR (Wobus et al., 2002) and
PDGFbR (Li et al., 2006), and thereby regulates cell
proliferation. On the cytoplasmic side, the tightly regulated
intracellular interaction between CD44 and Ezrin or NF2
proteins can be pivotal in determining whether cells
proliferate or apoptose (Morrison et al., 2001).
CD44 can be shed from the cell surface by proteolytic
cleavage. Increased plasma levels of soluble CD44 (solCD44)
have been observed in different malignancies (Sheen-Chen
et al., 1999; Yamane et al., 1999; Stickeler et al., 2000;
Yasasever et al., 2000; Molica et al., 2001; Niitsu and Iijima,
2002). Furthermore, studies with melanoma cell lines have
demonstrated that the cell proliferation-promoting effect of
See related commentary on pg 1321
& 2009 The Society for Investigative Dermatology www.jidonline.org 1471
ORIGINAL ARTICLE
Received 20 June 2008; revised 15 August 2008; accepted 27 August 2008;
published online 30 October 2008
1Department of Dermatology, Venerology and Allergology, Leipzig University
Medical Center, Leipzig, Germany; 2Institute for Molecular Cardiovascular
Research (IMCAR), RWTH Aachen, Aachen, Germany; 3Paul Flechsig
Institute of Brain Research, Universita¨t Leipzig, Leipzig, Germany and
4Medical Faculty Mannheim, Centre for Biomedicine and Medical
Technology Mannheim, University of Heidelberg , Mannheim, Germany
Correspondence: Dr Ulf Anderegg, Max-Bu¨rger-Forschungszentrum,
Johannisallee 30, 04103 Leipzig, Germany.
E-mail: Ulf.Anderegg@medizin.uni-leipzig.de
Abbreviations: ADAM, a disintegrin and metalloproteinase domain; ERM,
Ezrin-Radixin-Moesin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
HA, hyaluronic acid; MM, melanoma cell; MMP, matrix metalloproteinase;
PBS, phosphate-buffered saline; solCD44, soluble CD44
HA can be abolished in vitro and in vivo by solCD44 (Ahrens
et al., 2001b). This blocking of HA-induced proliferation was
strongly dependent on the ability of solCD44 to bind to HA
(Ahrens et al., 2001b), suggesting that solCD44 competes
with cell surface-bound CD44 for HA binding. Other groups
have found that shedding of the ectodomain of CD44 plays a
critical role in tumor cell migration (Goebeler et al., 1996;
Nagano et al., 2004). In addition, migrating tumor cells
traversing the extracellular matrix have been shown to
release membrane vesicles containing integrins, CD44, and
cytoplasma (Mayer et al., 2004), possibly part of the
detachment strategy that increases mobility of the tumor
cells. External cleavage of the CD44 ectodomain can be
followed by a second intramembraneous cleavage by a
g-secretase that releases the cytoplasmic domain of CD44
from the membrane into the cytoplasm (Nakamura et al.,
2004). This step perturbs the interaction between CD44 and
attached protein complexes, proteins of the cytoskeleton and
growth factor signaling cascades. Additionally, the cytoplas-
mic domain can enter the nucleus and act as a transcription
factor, changing the gene expression pattern of the cells
(Nagano and Saya, 2004; Nakamura et al., 2004). CD44
shedding may thus have important effects on tumor cell
behavior.
Several proteases have been implicated in the cleavage of
CD44 from the surface of tumor cells, the most important
being MMP14, ADAM-10, and ADAM-17. The involvement
of MMP14 in the shedding of the CD44 ectodomain has been
demonstrated in the fibrosarcoma HT1080 and gastric
carcinoma MKN-28 cell lines (Ueda et al., 2003). In the
context of MM, transfection of the melanoma cell line A375
with CD44 and MMP14 allowed the ability of MMP14 to
shed CD44 from the cell membrane to be demonstrated
(Nakamura et al., 2004), but the relevance of these findings to
the constitutive cleavage of endogenous CD44 in MM
remains unclear. Furthermore, inhibitor studies indicate that
CD44 shedding is not completely sensitive to matrix
metalloproteinase (MMP) inhibitors, indicating that another
type of protease must contribute to CD44 cleavage from the
membrane (Okamoto et al., 1999; Gasbarri et al., 2003). A
number of observations suggest that members of the ADAMs
(a disintegrin and metalloproteinase domain) family of
metalloproteinases that have important functions in extra-
cellular matrix processing, organogenesis, and hemostasis
(Reiss et al., 2006) are involved. ADAMs have been suggested
to be involved in the release of CD44 from the cell surface of
fibroblasts (Shi et al., 2001) and tumor cells (Nakamura et al.,
2004). In human glioma cells there is evidence that ADAM10
and ADAM17 mediate the effects of agents that stimulate the
shedding of CD44, but are not involved in constitutive CD44
shedding (Nagano et al., 2004).
Here we report expression of ADAM10 and ADAM17 and
to a lesser extent of MMP14 in human melanoma biopsies, as
well as in cultured CD44-positive human melanoma cells.
Functional studies employing specific inhibitors and siRNA
techniques revealed the involvement of ADAM10, but not of
MMP14 or ADAM17, in the constitutive shedding of native
CD44 from human melanoma cells. Confocal microscopy
revealed a colocalization of ADAM-10 and CD44 on the
surface of melanoma cells. Moreover, ADAM10 knockdown
augmented HA-induced proliferation of the cells in a CD44-
dependent manner. These data are consistent with the notion
that ADAM10 is critically involved in the constitutive
shedding of the CD44 ectodomain from human melanoma
cells to generate solCD44, a process that has impact on
melanoma cell proliferation.
RESULTS
The candidate CD44 sheddases ADAM-10, ADAM-17, and
MMP-14 are expressed in malignant melanoma cells in vivo and
in vitro
MMP14, ADAM-10, and ADAM-17 have all been implicated
in the shedding of the CD44 ectodomain, yet their relative
expression in human MM remains to be determined. We
therefore investigated the expression of these proteases in
healthy human skin and in a panel of malignant melanomas
of various types (superficial spreading melanoma n¼10,
nodular melanoma n¼8, skin metastases n¼5) using
established antibodies. Both ADAM-10 and ADAM-17 were
expressed by the tumor cells in 20/23 samples (Figure 1a
and b). MMP14 was also expressed on melanoma cells in 20/
23 samples, albeit at a weaker staining intensity (Figure 1c).
Note that CD44 is also prominently expressed by the
melanoma cells (Figure 1d). In normal skin, all three
proteases were detected in the epidermis and to a lesser
extent in dermal fibroblasts (Figure 1e–g). Based on these
in vivo expression data it appears that all of the three
proteases implicated in the shedding of CD44 are expressed
on tumor cells in tissue samples of melanoma.
To be able to perform functional experiments to address
the relative roles of MMP14, ADAM-10, and ADAM-17 in the
shedding of CD44 from MM, we next examined the level of
CD44 shedding in a panel of six MM cell lines. Of these, Bro
and HT144 showed the highest levels of constitutive
endogenous CD44 shedding (data not shown) and were
therefore selected for further studies. Both cell lines expressed
ADAM10, ADAM17, and MMP14 mRNAs, with ADAM10
expression being highest when normalized to the house-
keeping gene glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) in qPCR experiments (Figure 2a). In Western blot
analysis, both the inactive 90/125 kDa pro-forms and the 75/
100 kDa mature forms of ADAM 10 and ADAM 17 could be
detected. MMP14 was detectable by western blot analysis as
a single band of about 65 kDa (Figure 2b). MMP14 activity
was detectable in both cell lines using a MMP14 activity
ELISA (Figure 2c).
CD44 shedding from melanoma cells is sensitive to ADAM
inhibitors
To investigate the possible contribution of ADAM10 and
ADAM17 to the shedding of CD44 in MM cells, we first
employed two previously described ADAM-specific protease
inhibitors. One inhibitor, namely GI254023X, preferentially
blocks ADAM10 with a 100-fold higher specificity toward
ADAM10 than to other proteases, whereas the other,
designated GW280264X, blocks both ADAM10 and
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ADAM17 with comparable IC50 values (Hundhausen et al.,
2003; Ludwig et al., 2005). In cleavage assays we found by
ELISA that both inhibitors reduced the shedding of CD44 in
the MM cell lines (Figure 3) without exerting any toxic effects,
as assessed by trypan blue exclusion (data not shown). To our
knowledge this is the first evidence that that ADAM10 rather
than ADAM17 is involved in the constitutive shedding of
CD44 in MM cells.
Knockdown of ADAM10 but not of ADAM17 effectively
reduces CD44 shedding in melanoma cells
To confirm the findings obtained with the inhibitors that
suggested that ADAM10 rather than ADAM17 might be the
relevant CD44 sheddase in MM, we used a RNA knockdown
approach. The melanoma cell lines Bro and HT144 were
transfected with stealth siRNAs (Invitrogen, Karlsruhe, Ger-
many) specific for either ADAM10 or ADAM17 and subse-
quently mRNA and protein levels for ADAM10 and ADAM17
were determined. Specificity of the knockdown was con-
firmed using scrambled control siRNAs and cross detection of
ADAM10 mRNA expression in ADAM17 silenced cells and
vice versa (data not shown). All six different siRNAs specific
for ADAM10 or for ADAM17 specifically reduced the
respective mRNA levels over a time period from 24 to
96 hours after transfection. Likewise, ADAM10 and ADAM17
protein levels were effectively decreased from 48 until
96 hours after transfection by the respective siRNAs (Figures
4a, b, 5a and b) compared to transfection of MM cells with
scrambled control siRNAs.
We then assessed the effect of knockdown of ADAM 10
and ADAM17 on the shedding of CD44 by measuring the
concentrations of soluble CD44 in the culture supernatants of
siRNA-transfected melanoma cells. Importantly, knockdown
of ADAM10 (Figure 4c) but not of ADAM17 (Figure 5c)
effectively blocked the shedding CD44 into the culture
supernatant. However, decreased shedding was not accom-
panied by changed expression of CD44 on the cell surface as
assayed by flow cytometry (Figure S1) and Western blot (data
not shown). These data, together with the inhibitor studies
shown in Figure 3, provide strong evidence that ADAM10 is
crucially involved in the CD44 shedding process in human
melanoma cells.
MMP14 is not involved in constitutive CD44 shedding
To date, only indirect evidence has suggested a role for
MMP14 in the shedding of CD44 in MM cells (Nakamura
et al., 2004). We found little MMP14 expression in human
melanomas using immunohistochemistry (Figure 1). Further-
more, although MMP14 mRNA and protein were detected in
Bro and HT144 cell lines, MMP14 was expressed at
substantially lower amounts compared to ADAM10 in
Bro and HT144 cells, consistent with the finding of low
MMP14 activity in melanoma cells using functional assays
(Figure 2). To test the relative importance of MMP14 in CD44
shedding from melanoma cells, we again chose the siRNA
approach.
Sequence specific blocking of mRNA transcription led to
decreased MMP14 mRNA and protein expression levels in
the transfected cells (Figure 6a and b). Importantly, efficient
blocking of MMP14 expression did not change the release of
CD44 from the transfected cell lines (Figure 6c). Parallel
transfection of the cells with ADAM10-specific siRNA, and
cotransfection of an MMP14-siRNA and the ADAM10-
specific siRNA proved the specificity of the RNA knockdown
and furthermore demonstrated that only ADAM10-specific
siRNA treatment blocks CD44 shedding in the MM cells
(Figure 6a and c). Importantly, cotransfection of ADAM10-
and MMP14-specific siRNAs did not further decrease CD44
shedding compared to transfection with ADAM10-specific
siRNAs alone (Figure 6c).
Together, these data demonstrate that ADAM10, but not
ADAM17 or MMP 14, is the relevant protease involved in the
endogenous shedding of CD44 from human melanoma cells.
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Figure 1. Candidate sheddases as well as CD44 are expressed in malignant
melanoma. A representative example of a superficially spreading melanoma
(out of n¼ 10) is shown here, with prominent ADAM10 expression in tumor
cells (a). ADAM17 (b) shows a similar expression pattern but MMP14 (c)
shows a different signal distribution (red color). CD44 (d) is expressed on the
tumor cells as well. In normal skin ADAM10 (e), ADAM17 (f) and MMP14 (g)
are expressed at lower intensity and prevail in the epidermis. Specificity of the
staining was checked using an isotype control antibody (h). Scale bar¼
200mm.
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ADAM10 and CD44 colocalize, whereas ADAM17 and CD44
do not colocalize in Bro MM cells
To further substantiate the notion that ADAM10 expression is
involved in the shedding of CD44 from MM cells, we used
immunofluorescense techniques to determine whether CD44
and ADAM10 or ADAM17 colocalize on the cell membrane
of MM cells. Confocal laser scanning microscopy revealed
that CD44 and ADAM10 proteins could be found at the cell
membrane, and furthermore indicated that these two proteins
colocalize within the cell membrane (Figure 7a). These data
therefore indicate that ADAM10 and CD44 can be found
together in the same cellular compartment, providing
the necessary spatial proximity of the proteins for ADAM10
to be directly involved in CD44 cleavage. Conversely, no
colocalization of ADAM17 and CD44 could be detected
(Figure 7b) indicating that there is no constitutive interaction
between CD44 and ADAM17. These data could be also
confirmed for the melanoma cell line HT144 (data not
shown; see Figure S3).
ADAM10 knockdown stimulates melanoma cell proliferation in
a CD44-dependent manner
In a first attempt to investigate the functional relevance of
constitutive ADAM10 expression in melanoma cells we
examined its effect on tumor cell proliferation. As we had
previously shown that solCD44 reduces the proliferative
capacity of melanoma cells both in vitro and in vivo (Ahrens
et al., 2001b), we examined whether the blocking of CD44
shedding by ADAM10-knockdown changes the proliferation
rate of melanoma cells. For this purpose MM cells were
transfected with ADAM10-specific siRNA. In addition, we
silenced CD44 expression in combination with ADAM10,
which effectively abolished CD44 mRNA levels and CD44
shedding as shown by qRT-PCR (data not shown) or solCD44
ELISA (Figure 8b). First we show that ADAM10 silencing
significantly enhanced melanoma cell proliferation (Figure
8a) in the presence of coated or soluble HA. Importantly,
simultaneous knockdown of CD44 abolished the increased
proliferative response induced by ADAM10 silencing (Figure
8a). Further corroborative evidence for the notion that
silencing of ADAM10 stimulates cell proliferation in a
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synchronize the cells they were incubated overnight with medium containing
1% FCS. The cells were incubated with complete medium or with medium
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CD44-dependent manner was also obtained by comparing
the effect of ADAM10 silencing in three melanoma cell lines
differing in CD44 expression. The cell lines Bro and HT144
express CD44 and shed significant amounts of CD44. The
human melanoma cell line RPM-MC (Hoashi et al., 2001;
Morrison et al., 2001) expresses equivalent levels of
ADAM10 as Bro and HT144 cells, but it neither expresses
CD44 nor releases solCD44. The results of these experiments
showed that ADAM10 knockdown significantly induced cell
proliferation compared to scrambled siRNA treatment in both
of the CD44 expressing Bro and HT144 cell lines (Figure 8c).
Importantly, silencing of ADAM10 did not affect cell
proliferation in RPM-MC cells which do not express CD44.
Together with the data obtained using ADAM10 and CD44
cosilencing, these data indicate that ADAM10 mediates
shedding of the CD44 ectodomain that in turn strongly
affects the proliferation of MM cells.
DISCUSSION
Human melanoma cells are capable of shedding constitu-
tively the ectodomain of CD44, and our previous work has
shown that the resulting solCD44 abolishes proliferation of
MM in vitro and in vivo (Ahrens et al., 2001b). Until now, the
protease(s) responsible for this shedding has remained
obscure. The ADAMs, a family of zinc-dependent mem-
brane-associated proteases that cleave a variety of substrates
including growth factors, extracellular matrix proteins, and
transmembrane receptors, are prominently expressed in
many cancers such as in oral cavity, stomach, ovary, uterine,
colon, leukemia, prostate (reviewed in (Mochizuki and
120
100
80
60
40
20
0
120
100
80
60
40
20
0
120
160
140
100
80
60
40
20
0
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
sio
n 
(%
)
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
sio
n 
(%
)
so
IC
D4
4 
(ng
 m
l–1
) 120
160
140
100
80
60
40
20
0
so
IC
D4
4 
(ng
 m
l–1
)
48 hours 72 hours 96 hours24 hours
*
*
*
*
*
*
*
* *
*
*
*
*
*
*
*
*
*
* * * * * * * *
* *
* * * * * * * * * *
* * *
48 hours24 hours 72 hours 96 hours
24 hours 48 hours 72 hours 96 hours 24 hours 48 hours 72 hours 96 hours
Bro HT144
scr siRNA
A10-3
A10-2
A10-1
scr siRNA
A10-3
A10-2
A10-1
scr siRNA
A10-3
A10-2
A10-1
sc
r 
si
R
N
A
A1
0-
3
A1
0-
2
A1
0-
1
sc
r 
si
R
N
A
ADAM10
Actin
ADAM10
Actin
A1
0-
3
A1
0-
2
A1
0-
1
scr siRNA
A10-3
A10-2
A10-1
Figure 4. ADAM10 siRNA decreases ADAM10 mRNA and protein levels and efficiently reduces CD44 shedding. Growing cultures of MM cells were
transfected with specific and scrambled siRNAs. After various time points the ADAM10 mRNA expression was determined by real-time PCR (a). Parallel
cells were analyzed by immunoblotting for ADAM10 protein expression (b). Quantitation of solCD44 in the culture supernatants from the cells shows
that all three ADAM10-specific siRNAs but not the scrambled controls significantly block CD44 shedding (c). The mean and standard error from 5 independent
experiments is presented. *Po0.005.
www.jidonline.org 1475
U Anderegg et al.
ADAM10 Sheds CD44 From Melanoma Cells
Okada, 2007)). Here we show that ADAM10 and ADAM17
are constitutively expressed in human melanoma cells. More
importantly, we demonstrate that blockade of ADAM10
activity or its expression has a potent inhibitory effect on
CD44 shedding, and also strongly stimulates MM cell
proliferation in a CD44-dependent manner. Together, these
observations are consistent with the notion that ADAM10
plays a major role in regulating melanoma cell proliferation,
at least in part by controlling the shedding of the ectodomain
of CD44 from MM cells.
Is ADAM10 the only protease involved in constitutive
shedding of CD44 from MM cells? In addition to ADAM10,
ADAM17 and MMP14 have been suggested previously to
play a role in CD44 shedding. Using the well established
inhibitors GW280264X and GI254023X that have been
shown to inhibit ADAM10 and ADAM17 (Hundhausen
et al., 2003; Ludwig et al., 2005) together with siRNA
techniques, we clearly demonstrated that ADAM10 but not
ADAM17 is involved in the constitutive shedding of native
CD44 from MM cells. This is consistent with previous reports
that found that CD44 shedding was not sensitive to ADAM17
depletion in mouse monocytes and fibroblasts (Shi et al.,
2001). A possible involvement of MMP14 in CD44 shedding
has been suggested by cotransfection studies of MMP14,
CD44, and TIMPs in breast carcinoma, osteosarcoma (Kajita
et al., 2001), and melanoma cells (Nakamura et al., 2004).
However, it is important to note that cotransfection generates
dramatically changed molecular ratios between the putative
sheddases, their inhibitor proteins and CD44 compared to the
steady state levels of natively expressed proteins in untreated
cells. Indeed, we found little expression or activity of MMP14
in MM. Further, blocking its expression had no effect on the
endogenous constitutive cleavage of CD44 from MM cells,
ruling out a role for MMP14 in cleavage of CD44 in this
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context. Although other proteases such as ADAM9 have been
reported to be expressed in human malignant melanoma
(Zigrino et al., 2005), there is no evidence that they might be
involved in CD44 cleavage. Most importantly, our data show
that inhibition of ADAM10 alone has a dramatic effect on the
shedding of CD44 from MM cells, with functional
consequences for cell proliferation. Cell adhesion to HA
(Figure S1) and cell motility on HA (assayed by time lapse
videomicroscopy), however, were not changed significantly
by ADAM10 silencing (data not shown). This might be due to
the fact that the amount of membrane-bound CD44 on
the MM cells was not affected by ADAM10 knockdown
(Figure S2). These data strongly support the notion that
ADAM10 plays at least the major role in regulating shedding
of CD44 from MM cells.
The mechanism of CD44 cleavage by ADAM10 in MM
cells remains to be determined, and whereas it is likely that
CD44 is a direct target of ADAM10, we cannot currently rule
out the possibility that ADAM10 acts indirectly, for example
by activating another protease. ADAM10 has previously been
implicated in the cleavage of CD44 from glioblastoma cells,
where ADAM10-dependent shedding can be induced by
Ca2þ influx (Nagano and Saya, 2004). In these cells it has
also been demonstrated that EGF can induce ADAM10-
mediated cleavage of CD44 in a manner that is dependent on
Rac1 and mitogen-activated protein kinase activation (Murai
et al., 2004). Recent investigations with ovarian carcinoma
cell lines have also demonstrated that ADAM10 can initiate
cleavage of CD44 and CD171 in the endosomal compart-
ment, with the fragments subsequently being released in the
form of exosomes, within which cleavage continues (Stoeck
et al., 2006). Regarding a possible ADAM10 substrate
sequence on CD44, cleavage of the Axl receptor tyrosine
kinase by ADAM10 is critically dependent on membrane-
proximal sequences of the receptor (Budagian et al., 2005),
and the same may hold true for CD44. ADAM10 also
contains a sorting signal within its cytoplasmic domain that
can target it to adherens junctions, and this targeting is
required for ADAM10-mediated cleavage of E-cadherin
(Maretzky et al., 2005; Wild-Bode et al., 2006). In this
context it is interesting to note that CD44 can also localize to
adherens junctions (Kooy et al., 1999).
We observed a clear colocalization between ADAM10
and CD44, but not between ADAM17 and CD44. In this
regard it is worth noting that CD44 can interact with a variety
of other cell surface proteins, including integrins and various
growth factor receptors (reviewed in Ponta et al., 2003). The
colocalization between ADAM10 and CD44 also suggests
that the molecules are in the appropriate spatial proximity for
ADAM10-mediated cleavage of CD44 to function in cis.
However, we cannot rule out the possibility that ADAM10-
mediated cleavage of CD44 functions in trans. Indeed,
cleavage of ephrin-A5 by ADAM10 occurs in trans, with
ADAM10 and its substrate being on the membranes of
opposing cells (Janes et al., 2005).
We have previously reported that soluble CD44 inhibits
HA-stimulated proliferation of melanoma cells in vitro and
in vivo (Ahrens et al., 2001b). In this study we could
demonstrate that the silencing of ADAM10 suppresses
constitutive CD44 shedding and also promotes melanoma
cell proliferation. The effect of inhibiting ADAM10 expres-
sion/activity on MM cell proliferation was dependent on their
CD44 expression. This observation can be explained on a
number of levels: Reduced constitutive shedding of CD44 as
a consequence of ADAM10 knockdown could also possibly
increase the density of transmembrane CD44 on the cell
surface, leading to increased proliferation as a consequence
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Figure 6. MMP14 knockdown does not affect CD44 shedding in melanoma
cells. Growing cultures of MM cells were transfected with siRNAs against
MMP14, ADAM-10, a combination of both, or with scrambled siRNAs. After
48 hours the mRNA expression was determined by real-time PCR (a). After
72 hours cells were analyzed by immunoblotting for protein expression (b).
Quantitation of solCD44 in the culture supernatants from the cells by ELISA
after 72 hours culture shows that neither MMP14-specific siRNAs nor the
scrambled controls impair CD44 shedding (c). Cotransfection of ADAM10-
specific siRNA with MMP14-specific siRNA did not enhance the blocking
effect on CD44 shedding mediated by ADAM10-specific siRNA alone. The
mean and standard error from 3 independent experiments is presented.
*Po0.05; **Po0.005.
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of enhanced ligation of HA by the MM cells, which we have
previously shown promotes their proliferation (Ahrens et al.,
2001b). However, this is unlikely as we did not observe
changes in steady state cell surface levels of CD44 in
response to blockade of ADAM10 expression/activity as
assessed by FACS analysis (see Figure S1) and Western
blotting (data not shown). This stable CD44 surface expres-
sion could also explain unchanged cell functions that rely on
HA–CD44 interaction such as cell attachment (see Figure S2)
and motility on HA-coated surfaces. Another possibility is
that reduced levels of solCD44 as a result of blocking
ADAM10 expression/activity could decrease the interference
by solCD44 in the interaction between HA and membrane-
bound CD44, which would be consistent with our previous
findings that soluble CD44 can inhibit the HA-stimulated
proliferation of melanoma cells (Ahrens et al., 2001b).
Blocking of CD44 shedding might also change intracellular
signaling events. Proliferation of nonconfluent, growing cell
cultures depends on the interaction of the CD44 cytoplasmic
domain with Ezrin-Radixin-Moesin (ERM) proteins (Morrison
et al., 2001). On the other hand, dissociation of this
CD44–ERM complex results in NF2-mediated growth arrest
(Morrison et al., 2001). Shedding of the CD44 ectodomain is
followed by the sequential cleavage of the CD44 cytoplasmic
domain by a g-secretase (Nagano and Saya, 2004) in many
cells. It may be possible that following ADAM10-mediated
shedding of the CD44 ectodomain the CD44 cytoplasmic
domain is released from internal complexes with ERM
proteins, which then results in an antiproliferative signal.
Thus, inhibition of CD44 shedding by ADAM10 siRNA could
result in persistence of CD44–ERM–NF2 complexes, resulting
in a more efficient proliferation. Future work will focus on
deciphering which of these various possibilities accounts for
the effect of ADAM10 on MM cell proliferation.
How might the activity of ADAM10 be increased in MM
cells? Recent work suggests that ADAM10 activity is
upregulated in the context of squamous skin tumors by
kallikrein 6 (Klucky et al., 2007). Consistently, the postulated
cleavage site in the latent ADAM10 protein whose proteolysis
activates ADAM10 enzymatic activity shares similarities with
amino-acid sequences that are efficiently cleaved by kallik-
rein 6 (Angelo et al., 2006). To the best of our knowledge no
studies have examined the expression of kallikrein 6 in the
context of melanoma, and it will therefore be interesting to
examine whether kallikrein 6 might be responsible for the
ADAM10 expression and/or activity we observed in human
MM tumors and cell lines.
In conclusion, our data indicate that ADAM10 is the major
protease responsible for constitutive CD44 cleavage from
MM cells, and that its expression can impair tumor cell
proliferation in MM. Upregulation of ADAM10 expression or
activity, thus stimulating the production of solCD44 and at
the same time inhibiting MM cell proliferation, might
therefore represent a therapeutic approach for MM.
MATERIALS AND METHODS
Antibodies and inhibitors
Rabbit anti-human ADAM10 polyclonal antibodies, rabbit anti-
human ADAM17 polyclonal antibodies, and rabbit anti-human
MMP14 polyclonal purified IgG antibodies were purchased from
Chemicon Int. (Billerica,MA). Anti-CD44 antibody was purchased
from Bender MedSystems (Vienna, Austria). For Western blot
CD44 ADAM10/ADAM17 Merge
Figure 7. ADAM10 and CD44 colocalize on the cell membrane of MM cell line Bro, whereas ADAM17 does not co-localize with CD44 in resting MM
cells. Cells were cultured on glass cover slips, fixed and stained with anti ADAM10/goat anti rabbit-CY2 (green) and biotinylated antiCD44/Streptavidin-Alexa-
Fluor-555 (red) (a, upper line) or with ADAM17/goat anti rabbit-CY2 (green) and biotinylated antiCD44/Streptavidin-Alexa-Fluor-555 (red) (b, lower line).
Inspection of the stained cells with a confocal laser scanning microscope revealed ADAM10 expression in the cytoplasm and at the cell membrane,
whereas CD44 was expressed predominantly on the cell membrane. In the merged picture the yellow spots indicate colocalization of both proteins in the
cell membrane. Scale bar¼20 mm.
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development, anti-rabbit F(ab)-fragments coupled to horseradish
peroxidase (Santa Cruz Biotechnology Inc., Santa Cruz, CA) were
used. Equal loading and transfer of proteins was ensured using a
rabbit anti-human b-actin polyclonal antibody (Abcam, Cambridge,
UK). The metalloproteinase inhibitors GW280264X ((2R,3S)-3-
(formyl-hydroxyamino)-2-(2-methyl-1-propyl) hexanoic acid ((1S)-
5-benzyloxycarbamoylamino-1-(1,3-thiazol-2-ylcarbamoyl)-1-pentyl)
amide) and GI254023X ((2R,3S)-3-(formyl-hydroxyamino)-2-(3-
phenyl-1-propyl) butanoic acid ((1S)-2,2-dimethyl-1-methylcarba-
moyl-1-propyl) amide) were synthesized as described in US Patents
US 6 172 064, US 6 191 150, and US 6 329 400. The compounds
were assayed for inhibition of recombinant human ADAM17 and
ADAM10 ectodomains as described with final concentrations of
5mM (Hundhausen et al., 2003; Ludwig et al., 2005). The inhibitors
were dissolved in DMSO at 5mM and the control experiments were
performed by adding 1/1,000 volume DMSO.
Cell culture
The melanoma cell lines Bro (kindly provided by Dr J Eberle
Berlin (Lockshin et al., 1985)), and HT144 (kindly provided by
Dr van Muijen (van Muijen et al., 1995)) were cultured in
RPMI 1640 (Biochrom, Berlin, Germany) supplemented with 10 or
1% fetal bovine serum (PAA, Pasching, Austria) and maintained at
37 1C in a humidified 5% CO2 atmosphere. Cultures were passaged
by detaching the cells with trypsin/EDTA solution (Biochrom).
Experiments were started after 12 hours of serum starvation to
synchronize the cell cycles. For transfection, melanoma cells were
grown in six-well plates until they reached approximately 50%
confluence.
RNA preparation and real-time PCR
Total RNA was prepared using the innuPREP RNA Mini Kit
(Analytikjena, Jena, Germany). The quantity and quality of the
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Figure 8. ADAM10 silencing enhances cell proliferation in a CD44-dependent manner. MM cells (1104 cells per well) were seeded into a 24 well plate and
transfected with siRNAs as described. Proliferation was assayed by the wst-Proliferation test 48 hours after transfection of the cells. The proliferation in wells of
scrRNA-transfected cells was set to 100%. (a) Cell proliferation of Bro cells was determined after silencing of ADAM10 (A10-3), and after cosilencing of
ADAM10 (A10-3) and CD44 (CD44-2) simultaneously. (b) The effectiveness of gene silencing on the CD44 shedding was analyzed by CD44 ELISA. (c) ADAM10
silencing promotes cell proliferation in CD44 expressing cell lines Bro and HT144 whereas it has no impact on cell proliferation in the CD44 negative cell line
RPM-MC. The mean and standard error from 3 independent experiments is presented. *Po0.05.
www.jidonline.org 1479
U Anderegg et al.
ADAM10 Sheds CD44 From Melanoma Cells
RNA was determined by spectrophotometry (ND-1000; NanoDrop
Technologies Inc., Wilmington, DE). Total RNA (1 mg) from each
sample was used for first strand cDNA synthesis using M-MLV
reverse transcriptase (Promega, Madison, WI) following the manu-
facturer’s instructions. Real-time PCR was monitored by EvaGreen
fluorescence (Biotium Inc., Hayward, CA) using GenTherm DNA-
Polymerase (Rapidozym, Berlin, Germany) with 2.5mM MgCl2,
0.5mM Primer, 250mM dNTPs, and 0.5U polymerase per reaction
(20 ml) under primer-specific conditions. The following experimental
protocol for PCR reaction (40 cycles) was performed on a Rotor-
Gene 3000 cycler (Corbett Research, Sydney, Australia): denatura-
tion for 5minutes at 95 1C, followed by 40 amplification cycles at
95 1C (10 seconds), annealing under primer-specific conditions
(20 seconds), and extension for 30 seconds at 72 1C. Fluorescence
was measured for 15 seconds at 80–85 1C depending on the melting
temperature of the specific PCR product. Primers with the following
sequences were chosen: GAPDH (GenBank NM_002046): forward:
50-CTTCACCACCATGGAGAAGGC-30, reverse: 50-CCAGTGAGCTT
CCCGTTCAGC-30, annealing temperature 58 1C. ADAM-10 (Gen-
Bank NM_001110): forward: 50-CAAAGTCTGAGAAGTGTCGGG-30,
reverse: 50-CTGCACATTGCCCATTAATG-30, annealing temperature
60 1C. ADAM-17 (GenBank NM_003183): forward: 50-ACCTGAA
GAGCTTGTTCATCGAG -30, reverse: 50-CCATGAAGTGTTCCGATA
GATGTC-30, annealing temperature 60 1C. MMP-14 (GenBank
NM_004995): forward: 50-ACATTGGAGGAGACACCCAC-30, re-
verse: 50-TAGGCAGTGTTGATGGACGC-30; 20-50 oligoadenylate
synthetase (GenBank: NM_016816): forward: AGAAAGAGGGCG
AGTTCTCC, reverse: 50-GCATAGACCGTCAGGAGCTC-30; anneal-
ing temperature 60 1C. All Primers were obtained from Metabion
(Martinsried, Germany). To confirm the specificity of the amplified
DNA, a melting curve was determined at the end of each run. The
reaction efficiency was determined with a dilution series of plasmids
containing the PCR products. Genes were normalized to the
unregulated housekeeping gene GAPDH and the results were
expressed as ratio of target gene and GAPDH expression (arbitrary
units). Control experiments were also performed to ensure that
GAPDH expression was not differentially regulated under the
experimental conditions employed, and expression of additional
house keeping genes was also analyzed to verify the reliability of
normalization relative to GAPDH.
CD44 ELISA
Soluble CD44 protein in culture supernatants was quantified using
an ELISA kit from Bender MedSystems according to the manufac-
turer’s instructions. All samples were assayed in triplicate.
Immunohistochemistry
Cryostat sections of superficial spreading melanoma were incubated
with the anti-ADAM10, ADAM-17, anti-MMP14, or anti-CD44
antibodies for 1 hour, followed by avidin–biotin complex
technique according to the manufacturer’s recommendation (super-
sensitive multilink alkaline phosphatase ready-to-use detection
system; Biogenix, San Ramon, CA). Bound proteins were detected
colorimetrically using the New Fuchsin substrate system
(DAKO, Hamburg, Germany). As a negative control, the same
procedure was performed with a rabbit IgG control antibody.
The study was conducted according to Declaration of Helsinki
Principles.
Immunofluorescense staining
Bro and HT144 cells were cultured on cover slips for 24 hours in
complete medium. The medium was removed and the cells were
washed with warm phosphate-buffered saline (PBS). Next the cells
were fixed with cold paraformaldehyde (4% in PBS) for 15minutes.
After rinsing with PBST (PBSþ 0.1% Tween20) the fixed cells were
pre-blocked with PBST containing 5% goat serum for 30minutes.
Cells were stained with anti-ADAM10 or anti-ADAM17 for
45minutes at room temperature and after several washes with PBST
a CY2-labeled goat-anti-rabbit antibody was added. In a second
round, a biotinylated antiCD44-antibody was used as the primary
antibody that was secondarily detected with Stretavidin-Alexa555.
Normal rabbit and mouse IgG were used as controls.
Finally the sections were extensively washed with PBST, briefly
placed in distilled water, mounted on fluorescence-free slides, air
dried, and cover slipped with Entelan (dissolved in toluene; Merck,
Darmstadt, Germany). The objects were viewed using a Zeiss
confocal laser scanning microscope (LSM 510). Confocal images of
Cy2 fluorescence were obtained with the argon laser (488 nm) and
emission filter BP 505–530. The HeNe 1 laser (543 nm) and the
emission filter BP 560–615 were used to detect Cy3 fluorescence.
Transfection of melanoma cells with siRNA
siRNA (Stealth Select RNAi) specific for ADAM10 (Stealth Select
RNAi HSS100165-67), ADAM17 (Stealth Select RNAi HSS110434-
36), and MMP14 (Stealth Select RNAi HSS106639-41) as well as
scrambled siRNA (Stealth RNAi Negative Control (High and Medium
GC)) were purchased from Invitrogen.
MM cells with a confluence of 30–50% were transfected with
either 40 pmolml1 of gene-specific siRNA or 40 pmolml1 of
scrambled control siRNA using Lipofectamine RNAiMax Transfec-
tion Reagent (Invitrogen) according to the manufacturer’s instruc-
tions. After various times of incubation, transcript levels of the gene
of interest were detected by quantitative RT-PCR and protein
expression was analyzed by Western blotting. The influence of the
treatment on CD44 shedding was monitored by ELISA. To control for
transfection efficiency, FITC-labeled control siRNA (Santa Cruz,
Heidelberg, Germany) was transfected into the cells in parallel
experiments. This control indicated a transfection efficiency of
between 60 and 85% 48hours after transfection as measured by flow
cytometry (data not shown). Off target effects were evaluated by
analysis of ADAM10 mRNA expression in ADAM17-silenced cells
and vice versa. Unspecific knockdown could be excluded by this
method. Silencing of MM cells was achieved without eliciting
critical stress responses confirmed by qRT-PCR of the stress gene 20-
50 oligoadenylate synthetase (Sledz et al., 2003; Scacheri et al.,
2004).
Western blot analysis
Western blot analysis of endogenous ADAM10 and ADAM17 was
performed as described previously (Hundhausen et al., 2003;
Ludwig et al., 2005). In brief, the cells were washed with PBS and
directly lysed in Triton buffer (20mM Tris-HCl, pH 7.6; 0.5M NaCl,
0.5% Triton X-100). The protein concentration in the lysates was
determined using the Advanced Protein Assay Reagent from
Cytoskeleton (Denver, CO), and equivalent amounts of protein were
subjected to SDS-PAGE under reducing conditions using 8–16% Tris-
Glycine gels (Lonza, Bruxelles, Belgium). Proteins were transferred
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onto PVDF membranes (Hybond-P; Amersham, Freiburg, Germany).
Blocking was performed for 1hour with 5% non-fat dried milk powder
in PBS. The membranes were incubated with dilutions of rabbit
antiserum against ADAM10 (1mgml1 in PBS containing 0.01%
Tween 20 and 5% BSA) or rabbit antiserum against ADAM17
(1mgml1) combined with a rabbit-anti b-actin antibody (0.5mgml1)
for a loading control. Bound Ig was detected with HRP-coupled goat
anti-rabbit Ig (40ngml1 in PBS containing 0.01% Tween 20 and 5%
non-fat dried milk powder), followed by incubation with chemilumi-
nescence substrate (ECL; Pierce, Rockford, IL). Chemiluminescent
signals were recorded on a luminescent image analyzer (MultiImage
Light Cabinet; Alpha Innotech, San Leandro, CA).
Proliferation assay
Twenty-four-well flat bottom plates (Nunc Maxisorb) were coated
overnight at 4 1C with 300ml HA (1.0mgml1 in 50mM NaHCO3
buffer, pH 9.6) that had been heat inactivated for 20minutes at
100 1C. 3 104 cells per well were seeded and cultured overnight.
Cells were transfected with the siRNAs (40 pmolml1) and cultured
for further 48 hours. To measure cell proliferation, the wst-prolifera-
tion assay (Roche Applied Science, Mannheim, Germany) was
performed according to manufacturer’s protocol. In some experi-
ments soluble HA (0.5mgml1 in complete culture medium) was
added 6 hours after transfection. Statistical analysis of the data was
performed using the Student’s t-test. All probes were performed as
quintuplicate samples.
Statistical analysis
All data are expressed as the mean±SEM. Statistical analysis was
performed with the SigmaPlot9 software (Systat, Erkrath, Germany)
using the Student’s t-test.
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SUPPLEMENTARY MATERIAL
Figure S1. ADAM10 silencing does not change CD44 surface expression.
Figure S2. ADAM10 silencing does not change significantly cell attachment to
HA-coated surfaces.
Figure S3. ADAM10 and CD44 colocalize on the cell membrane of MM cell
line HT144, whereas ADAM17 does not localize with CD44 in resting MM
cells.
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